#Australia #Sydney #Clarity Pharmaceuticals #Nusano #copper-67

Clarity Pharmaceuticals and Nusano's Landmark Agreement

In a significant advancement for cancer treatment, Clarity Pharmaceuticals (ASX: CU6) has signed a groundbreaking Supply Agreement with Nusano, Inc. This collaboration aims to leverage the capabilities of copper-67, a therapeutic radioisotope known for its promising effectiveness in oncology.

The Role of Copper-67 in Cancer Treatment

Copper-67 is hailed for its potential in enhancing treatment outcomes for cancer patients. Clarity, a clinical-stage radiopharmaceutical company, is focused on developing innovative solutions that improve results for patients battling serious health conditions, especially cancer. With this agreement, Clarity aims to bolster its resources, preparing to conduct critical phases of its clinical trials.

Details of the Supply Agreement

The Supply Agreement with Nusano, effective from October 16, 2025, extends for an initial period of three years with automatic two-year renewals. Nusano's state-of-the-art facility in West Valley City, Utah, is set to commence operations in late 2025, with the supply of copper-67 expected to start mid-2026. The company's advanced accelerator-based technologies cater to large-scale production of copper-67, ensuring a reliable and efficient supply line for Clarity's clinical and commercial needs.

Benefits of Collaborating with Nusano

Nusano's focus on producing a variety of radioisotopes signifies a robust partnership for Clarity, as it seeks to expand its network of U.S.-based suppliers. Notable partners include NorthStar Medical Radioisotopes, LLC and Idaho State University's Idaho Accelerator Center. Dr. Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, voiced enthusiasm, highlighting that this agreement is pivotal for preparing their registrational Phase III clinical trial for 67Cu-SAR-bisPSMA, a product aimed at improving treatments for men suffering from prostate cancer.

The Future of Radiopharmaceuticals

Dr. Taylor emphasized the increasing importance of reliable and sustainable isotope supply chains. He pointed out the historical challenges faced with traditional radiopharmaceutical production methods, especially those dependent on nuclear reactors, which have implications for timely patient care. The transition to using copper-67, produced through less resource-intensive methods, marks a critical step toward sustainability in the oncology sector.

Chris Lowe, CEO of Nusano, highlighted the company’s mission to innovate and stabilize the supply chains of essential radioisotopes. He expressed excitement about working with Clarity, underlining Nusano’s unique position as the only radiopharmaceutical company engaged in clinical trials using copper-67.

Moving Towards a Sustainable Future

The collaboration aims to address and minimize supply chain risks by establishing enriched stable isotope productions for the raw materials required in creating copper-67. These developments are crucial not just for Clarity but for the broader landscape of cancer treatment, which currently faces pressing demand for effective and dependable therapies.

As Clarity resumes its exploration of copper-67 in clinical settings, it positions itself at the forefront of the radiopharmaceutical industry, keen on reinforcing its operational framework while paving the way for further clinical advancements in oncology treatment.

Conclusion

This strategic Supply Agreement with Nusano signifies a crucial milestone in Clarity's journey towards enhancing cancer treatment outcomes. By ensuring a dependable supply of copper-67, Clarity stands to reshape therapeutic approaches in oncology and significantly impact patient lives positively. As operations ramp up in Utah, the medical community and patients alike await the forthcoming developments with anticipation.